Buscar

Renown Health and the University of Nevada, Reno School of Medicine give the gift of early diagnosis and disease prevention this holiday season.   With the season of giving upon us, give yourself the gift of health. The Renown Institute for Health Innovation (IHI) and the University of Nevada, Reno School of Medicine (UNR Med) are excited to offer a free Enhanced Liver Fibrosis (ELFTM) test to patients at risk for a common type of liver disease, e.g. metabolic and nonalcoholic steatohepatitis (M/NASH), and who enroll or are currently enrolled in the Healthy Nevada Project. The ELF Test is an FDA (Food and Drug Administration) approved non-invasive test to help identify people most at risk for liver scarring, e.g. cirrhosis, and allows doctors to intervene before irreversible damage occurs. If undetected and untreated, M/NASH can result in liver cirrhosis which could require liver transplantation or lead to death. This test is important as the symptoms of M/NASH can be silent or non-specific, making it difficult to diagnose.  “There are currently more than 11,000 people across the U.S. on the national liver transplant waiting list, and with the heightened prevalence of NAFLD and M/NASH, this number is projected to keep rising; however, with research such as the ELF Test at our disposal, we are continuing to find ways to improve the health of those at risk for advanced liver disease,” said Bill Plauth, MD, Chief Medical Officer for Renown Health and Associate Dean of Clinical Affairs at UNR Med. “We encourage our community to participate in this early risk detection. Through this sophisticated, noninvasive, blood test, our physicians and Advanced Practice Providers can better evaluate liver fibrosis to help those affected and enable researchers to improve the prevention and treatment of nonalcoholic liver disease as a whole.”  This liver health-focused sub-study of the Healthy Nevada Project seeks to enhance the understanding of both NAFLD and M/NASH and to help inform the development of treatment options for these conditions, as few currently exist. “Providing access to cutting-edge innovations such as the ELF Test is critical for both participants and the physicians and advanced practice providers that care for them.” said Joseph Grzymski, PhD, principal investigator of the Healthy Nevada Project and the Liver Disease Study and research professor at UNR Med. Those interested in determining their risk for M/NASH and its progression are encouraged to enroll in the Metabolic & Nonalcoholic Steatohepatitis study. Those who have consented and participated in the M/NASH research will be eligible and contacted with more information on how to receive the ELF Test. The Renown IHI is also happy to connect with physicians and Advanced Practice Providers interested in having their patients enroll in the Healthy Nevada Project and join the study. For members of the community who would like more information and learn how to enroll, please contact the Renown IHI at RenownIHI@renown.org or (775) 982-6914 to be connected to a Genomic Representative. About the ELF™ Test  The ELF Test is a noninvasive blood test that can quickly identify which patients are at an elevated risk for developing cirrhosis and other liver-related clinical events (LREs). In contrast to standard liver enzyme tests that reflect liver damage that has already occurred, the ELF Test combines three serum direct biomarkers of active fibrosis. The ELF Test algorithm measures each of these biomarkers to create an ELF score, which can be used as an aid to assess the risk for future disease progression. Doctors may use this ELF score to help evaluate if a patient requires increased medical care and monitoring for their condition. Individuals interested in determining their risk for NASH and its progression are encouraged to enroll in the Nonalcoholic Steatohepatitis Liver Disease Genome Atlas study. Those who have already consented and participated in the study will be contacted with more information on how to receive an ELF blood test. Para obtener más información o para inscribirse, comuníquese a la casilla de correo RenownIHI@renown.org o al teléfono (775) 982-6914. In the U.S., the ELF Testing Service is available from Brio Clinical, Inc., a CLIA-certified laboratory offering specialized testing throughout the United States. Brio Clinical is regulated under CLIA as qualified to perform high complexity testing.

Leer más About Give the Gift of Health This Season with ELF Testing

Begin a new year on the traditional lunisolar Chinese calendar and help support Panda Express® locations - including the new Panda Cares® Center of Hope that has opened to serve pediatric patients and families throughout northern Nevada. This Lunar New Year, you can join local child, Emmalee Sutton, the Renown Health Foundation and Panda Express® through its philanthropic arm, Panda Cares® , to help children and their families receiving care at Renown Children’s Hospital. El sábado, 20 de febrero, los miembros de la comunidad pueden apoyar a los pacientes más jóvenes de Renown haciendo un pedido en línea en una ubicación de Panda Express® cercana utilizando el código 902354. Renown Children’s Hospital recibirá el 28 % de las ganancias de los pedidos en línea realizados con ese código. Ese mismo día, los colaboradores también pueden visitar la ubicación de Panda Express en Plumb Lane, Reno, donde donarán el 20 % de la recaudación en persona al Renown Children’s Hospital. (Presente este folleto en el momento de la compra).  Los clientes de Panda Express® y sus asociados en el norte de Nevada y el noreste de California han recaudado casi $500,000 para el Renown Children’s Hospital desde 2007. En 2020, se recaudaron más de $138,000 para el Panda Cares® Center of Hope en el Renown Children’s Specialty Center, que abrió sus puertas en el Renown Children’s Hospital ubicado dentro del Renown Regional Medical Center en 1155 Mill St. en Reno, Nevada. El Panda Cares® Center of Hope no solo brinda atención a niños, sino que también brinda apoyo integral a toda la familia. Similarly, it creates an environment that reduces stress, promotes healing, and provides a superior patient and family experience. “The Panda Cares® Center of Hope at Renown Children’s Hospital is special because it upholds Panda Express® ’ mission and values of being proactive, having respect for each other, learning and growing, and giving time and resources back to the community. The Center also supports each child’s well-being, including their physical, emotional, mental and spiritual needs,” says Tony Slonim, MD, DrPH, Renown’s President and CEO. “We are grateful for our partnership with the team at Panda Express® , who are as passionate as we are about children’s health, and helping us provide exceptional care for children.” “The Panda Cares® Center of Hope at Renown is the first-ever in northern Nevada, and we are excited to be able to provide the highest level of care for children and teenagers in northern Nevada who have chronic health conditions. Specifically, we offer ongoing treatment, health management, and age-appropriate specialty medical services including; pediatric nephrology, pediatric endocrinology, pediatric neurology, pediatric pulmonary, pediatric infectious diseases, medical genetics and adolescent medicine- all in one beautiful, new, convenient, family-friendly facility,” says Max Coppes, M.D., Ph. D., MBA, Nell J. Redfield Chair of Pediatrics at the University of Nevada School of Medicine and pediatrician-in-chief at Renown Children's Hospital.  A Partnership for Health & Education of Underserved Youth “This partnership allows Renown Children’s Hospital to continue to strengthen regional services and increase Panda’s visibility within our growing community,” says Lawrence Duncan - VP & Administrator for Renown Women & Children’s Hospital & Administrator the Institute for Cancer. “El año pasado, 21,930 niños enfermos recibieron atención en Renown Children’s Hospital. To date, Panda Express® has provided us significant financial support to assist us as a charitable, non-profit organization in providing health and healthcare to every child, regardless of illness, injury, insurance, or ability to pay.” “Renown Health Foundation appreciates Panda Cares® ’ generosity year after year, and the unwavering support of our community to make the Panda Cares® Center of Hope and Saturday’s fundraiser a success,” said Kiemmy Thai, MBA, Foundation Manager of the Children's Hospital at Renown. “Our hope is that you and your family can enjoy a nice meal from Panda Express® together, knowing your contribution makes it possible for pediatric champions like Emmalee to continue receiving the best care close to home.” The Panda Cares® Center of Hope has already helped hundreds of local pediatric patients and their families feel more comfortable and relaxed while being cared for in the hospital. Watch Renown Children’s Hospital and Children’s Miracle Network Hospitals’ newest Champion Child Ambassador, Emmalee Sutton, tour you through this new, fun and family-friendly health care environment.  “We are very fortunate to have such generous partners like the people behind Panda Express® who want to help our patients and their families, as well as our pediatric care teams,” said Dr. Sonia Budhecha, pediatric pulmonologist at Renown Children’s Specialty Care Center. “This Center has helped many young patients, and their parents, feel more comfortable along their healing journey, contributing to an even more positive experience here at Renown Children’s Hospital.” For more opportunities to support pediatric patients in our area, please visit renown.childrensmiraclenetworkhospitals.org/.   About Renown Children’s Hospital Renown Children’s Hospital is the only dedicated children’s hospital in northern Nevada, and offers a variety of programs and services designed specifically to care for the community's families. It has the region’s only Children’s ER and Pediatric ICU. Renown Children’s Hospital is the only hospital affiliated with Children’s Miracle Network Hospitals (CMNH) in the region and local CMN Hospitals' programs and events directly benefit children in the Truckee Meadows. It is also the only hospital in the region affiliated with CHA (Children’s Hospital Association). For more information, visit renown.org/children. Acerca de Panda Express® Con la misión de inspirar una vida mejor, Panda Express, una compañía pionera chino-estadounidense, es el mayor concepto gastronómico asiático de Estados Unidos. De propiedad familiar y operada desde 1983 por los cofundadores y codirectores ejecutivos Andrew y Peggy Cherng, Panda Express es conocida por crear una amplia variedad de recetas pioneras en la industria, que incluye su exitoso Original Orange Chicken® y el galardonado Honey Walnut Shrimp, que han definido la categoría de la auténtica cocina chino-estadounidense. Each dish at Panda Express, including the Wok Smart® selections, is thoughtfully crafted with quality ingredients and inspired by bold Chinese flavors and culinary principles. La marca de restaurante tiene más de 2,000 ubicaciones en todo los EE. UU. y ha introducido la opción chino-estadounidense en más de diez países internacionales. Impulsada por esta familia global de asociados, Panda Cares, la rama filantrópica de la organización, ha recaudado más de $212 millones e innumerables horas de voluntariado para mejorar la salud y la educación de más de 12 millones de jóvenes, así como para apoyar a las comunidades necesitadas desde 1999. Para obtener más información, visite pandaexpress.com o encuéntrenos en Facebook, Twitter o Instagram. Acerca de Children’s Miracle Network Hospitals Children’s Miracle Network Hospitals® recolecta fondos y crea conciencia para 170 hospitales miembros que brindan 32 millones de tratamientos cada año a niños en todos los EE. UU. y Canadá. Donations stay local to fund critical treatments and healthcare services, pediatric medical equipment and charitable care. Desde 1983, Children’s Miracle Network Hospitals ha recaudado más de $7 mil millones, mayormente $1 por vez a través del ícono del globo milagroso de la organización. Its various fundraising partners and programs support the nonprofit's mission to save and improve the lives of as many children as possible. Find out why children's hospitals need community support, and learn about your member hospital, at CMNHospitals.org and facebook.com/CMNHospitals.

Leer más About Take a Tour of the New Panda Cares Center at Renown Children's Hospital

Clinical researchers with the Healthy Nevada Project co-author research paper with findings that emphasize the need for a comprehensive approach to breast cancer risk assessment – including a focus on genetic medicine – to help ensure that individuals at high risk are identified and supported proactively rather than reactively.  Breast cancer is a leading cause of cancer death among women in the United States. According to the American Cancer Society, about 1 in 8 women will develop breast cancer and about 1 in 39 women will die from breast cancer. Breast cancer is associated with increased age, hereditary factors, obesity, and alcohol use. Since 1990, breast cancer death rates have declined progressively due to advancements in treatment and detection. In Nevada there are an estimated 2,310 new breast cancer cases a year, and genetic mutations such as in the genes BRCA1 or BRCA2 remain a top risk factor for this prevalent disease. Recognizing the urgency for progress in breast cancer research, a collaborative effort between physicians, advanced practice providers and scientists from the Healthy Nevada Project® (HNP) and Helix have unveiled groundbreaking research. This study explores how genetic screenings are a necessary supplement to traditional testing methods, together offering more accurate insights into a patient's likelihood of developing breast cancer in the future. HNP is operated by Renown Genomic Medicine and the Institute for Health Innovation and is one of the largest community-based population health studies in the country. Their team works in collaboration with Helix, a leader in precision health that delivers comprehensive genomic solutions. Together, this dynamic partnership aims to understand breast cancer risk factors and pave the way for more effective preventative measures. The combined research team studied 25,591 female HNP participants to evaluate the performance of different genetic screening approaches to identify women at high risk of breast cancer. The results of this research suggest that a combined monogenic, or single-gene, and polygenic, or multi-gene, approach to breast cancer screenings helped produce more accurate results and more closely identify study participants who have a high genetic risk of developing the disease. "Based on this research, we are advocating a shift in approach which would improve breast cancer risk assessment through a combination of effective family history ascertainment and genetic screening,” said Joseph Grzymski, PhD, principal investigator of the Healthy Nevada Project, research professor at the University of Nevada, Reno School of Medicine and co-author of the breast cancer research paper. “This tailored approach, founded on the assessment of individual genetic risk, not only intends to elevate patient well-being but also will improve efficiency and equity in healthcare." Complementing the team’s research on leveraging genetics to identify women at low genetic risk of breast cancer that could safely defer mammogram screenings by five to 10 years that was released in late 2023 in JAMA Oncology, the study suggests that incorporating genetic information can assist in personalizing breast cancer screenings and optimizing the use of screening resources. "Existing disparities persist across various facets of breast cancer screening and treatment; however, genetic screening is clearly a powerful tool to help facilitate early intervention for those at higher risk,” said Jamie Schnell Blitstein, APRN, a primary care nurse practitioner at Renown Health and co-author of the breast cancer research paper. “By placing a heightened focus on risk, we underscore the pivotal role of preventative breast cancer screening.” Despite the availability of effective methods for early screening, co-authors of this research found that 78 percent of women with a family history of breast cancer had their risk ascertained only after a breast cancer diagnosis. The findings emphasize the need for a comprehensive approach to breast cancer risk assessment – including a focus on genetic medicine – to help ensure that individuals at high risk are identified and supported proactively rather than reactively.  “These findings that can profoundly impact how healthcare is delivered were only made possible by all the participants who were willing to consent to research,” said Alex Bolze, PhD from Helix and co-author of the publication. “Broad-scale collaboration projects like these between Renown Health and UNR that engage large populations where participants share both their genetic information as well as electronic health records drive advancements in preventative medicine, as well as fundamental biological research.”   The research paper was officially accepted on Jan. 29, 2024, and will be published by Elsevier, Inc. on behalf of the American College of Medical Genetics and Genomics. The contents of the paper will appear in the international journal Genetics in Medicine Open. Read the full article by visiting sciencedirect.com. The Healthy Nevada Project is currently recruiting new study participants. Free to all Nevadans with a saliva sample or blood draw, participants and their referring providers receive access to whole-exome sequencing and clinical grade results that help provide insight into their unique genetic risks tied to heart disease and certain cancers. If you are interested in enrolling in the study, schedule a Virtual Consent Appointment through MyChart or contact the Renown Institute for Health Innovation at RenownIHI@renown.org or (775) 982-6914 to be connected to a Genomic Representative. About Renown Health Renown Health is the region’s largest, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Con una fuerza laboral diversa de más de 7,000 empleados, Renown ha fomentado una cultura de excelencia, determinación e innovación de larga data. La organización se compone de un centro de urgencias, dos hospitales de cuidados agudos, un hospital infantil, un hospital de rehabilitación, un grupo médico y una red de atención de urgencias y Hometown Health, la compañía de seguros sin fines de lucro más grande de la región y de propiedad local, Hometown Health. Renown is currently enrolling participants in the largest community-based genetic population health study, the Healthy Nevada Project®. To join the Renown Health team, visit renown.org/careers. Acerca de Helix Helix es la compañía líder en genómica y vigilancia viral de la población cuyas operaciones se basan en el cuidado clínico, la investigación y el análisis de datos. Helix enables health systems, life sciences companies, payers, and government partners to accelerate the integration of genomic data into patient care and public health decision-making. Learn more at helix.com.

Leer más About Research Shows Genetic Approaches to Breast Cancer Screenings Yield More Accurate Results

Donors, Orvis School of Nursing at University of Nevada, Reno and Renown Health create history by awarding tuition assistance to 29 nursing students and creating a future academic and career pipeline. The University of Nevada, Reno has officially begun its yearlong sesquicentennial celebration (October 2023 and through October 2024). Today, a celebration was held as donors, Renown Health and the University of Nevada, Reno Orvis School of Nursing awarded 29 nursing students with tuition support as part of the Gerald “Jerry” Smith Academic-Practice Partnership established with the Renown Health Foundation. The Practice Partnership is named in honor of the late Jerry Smith of the Nell J. Redfield Foundation and supported by a generous lead gift from the Redfield Foundation and Stephanie Kruse, owner of KPS3 and chair of the Renown Health Foundation Board as they work to create a sustainable nursing workforce in northern Nevada for years to come. Kruse made a generous planned gift to the Renown Health Foundation and the Renown Nursing Excellence Endowment Fund. This was the lead gift for the endowment, after a significant cash gift to the Nursing Education Fund last summer. Kruse of Reno was recently awarded the prestigious 2023 Trustee of the Year Award from the Nevada Hospital Association for her exceptional leadership; professional excellence; outstanding achievements; innovative accomplishments and extraordinary compassion in caring for the community. The Gerald “Jerry” Smith Academic-Practice Partnership recipients receive funding for tuition, books, and nursing fees, along with a guaranteed career in nursing with Renown Health following graduation and license obtainment. Eligible University of Nevada, Reno Orvis School of Nursing students, Nevada residents and those committed to working at Renown for at least three years post-graduation who are interested in applying for the tuition support can find the application in Canvas, University of Nevada’s learning management system. “Despite steady growth in the number of new nursing graduates from Nevada nursing programs and registered nurses moving to Nevada from other states, our state is in need of additional registered nurses simply to meet the increased population growth and demand,” noted Brian Erling, MD, MBA, President & CEO of Renown Health. “The daughter of a nurse and a former nurse herself, Stephanie understands the importance of attracting and retaining nurses within our healthcare systems. Stephanie has made a significant and lasting contribution by helping to train and grow the next generation of nurses and we so appreciate her service, and her many contributions to Renown and our community.” "Since our University first welcomed students to classes in 1874, the institution has been a place where dreams can be realized for the good of all. We are incredibly grateful for the Gerald ‘Jerry’ Smith Nursing Academic-Practice Partnership,” Brian Sandoval, President, University of Nevada, Reno (UNR) said. “The tuition support not only impact the lives and dreams of the nursing students being honored today, but positively influences the overall health of our community by ensuring that excellent healthcare professionals stay right here in northern Nevada.” “Jerry Smith had a strong belief in community collaboration, and we are beyond proud that this partnership is named in his memory. He would be thrilled to see the impact these gifts are having on these nursing students today,” said Greg Walaitis, Chief Development Officer for Renown Health Foundation. “Stepanie Kruse works tirelessly to improve access to better health and human services, and she is now encouraging others to join the fight by donating to the Gerald “Jerry” Smith Academic-Practice Partnership fund at Renown to help fund additional tuition assistance and support nurse education for our state. Her goal is to be able to provide full support to each of the 192 students in the Orvis School of Nursing program each year.” According to a white paper published by the Nevada Health Workforce Research Center (the Center) in December 2022, analysis by the Center revealed persistent, widespread health professional shortages in Nevada. Despite steady growth in the number of new nursing graduates from Nevada nursing programs and registered nurses moving to Nevada from other states, the Center estimated that Nevada currently needs over four thousand additional registered nurses simply to meet the national population-to-RN average. The partnership allows the Orvis School of Nursing to expand its graduating classes by 8 additional students a year. “At Renown, we take pride in placing an emphasis on education and career development. Partnering with the Orvis School of Nursing to create an academic pipeline is imperative for addressing the nursing shortage in Nevada,” said Melodie Osborn, Chief Nurse Executive at Renown Health. “Renown Health and the Orvis School of Nursing’s collaboration has been longstanding, and accomplishing this milestone reaffirms our partnership and our long legacy that both organizations have to nursing and education.” In addition to announcing the Practice Partnership, the Orvis School of Nursing has merged the traditional Bachelor of Science in Nursing program with the Accelerated Bachelor of Science in Nursing program. This merger has expanded the traditional Bachelor of Science in Nursing program from 72 students to 96 students admitted twice per year. The Bachelor of Science in Nursing program now admits a total of 192 students in the program each year. “We are excited to be accepting our first class of Gerald “Jerry” Smith Academic-Practice Partnership nursing students and to be increasing the number of nursing students who can enroll in the Orvis School of Nursing’s BSN program,” said Cameron G. Duncan, Interim Dean of the Orvis School of Nursing. “It’s integral for nursing students to get hands-on experience in an environment that places an emphasis on quality and excellence, which is why we’re proud to collaborate with Renown Health. We are so appreciative of Stephanie and the generous donors who will make education possible for students who might otherwise not be able to pursue a career in nursing.” Founded in 1864, Washoe County Hospital (which later became Renown Health) was the first hospital to open after Nevada became a state and is now the state’s largest not-for-profit healthcare organization and #1 hospital in Nevada (US News & World Report). Founded in 1956, the Orvis School of Nursing (OSN) is the oldest school of nursing in the state and committed to serving the healthcare needs of the people of Nevada through excellence in teaching, research, and service. In 2021, Renown Health affiliated with the University of Nevada Reno, School of Medicine creating the state’s first integrated health system. Acerca de Renown Health Renown Health es la red de atención médica integrada de administración local y sin fines de lucro más grande de la región, que presta servicios a Nevada, Lake Tahoe y el noreste de California. With a diverse workforce of more than 7,000 associates, Renown has fostered a longstanding culture of excellence, determination, and innovation. La organización se compone de un centro de urgencias, dos hospitales de cuidados agudos, un hospital infantil, un hospital de rehabilitación, un grupo médico y una red de atención de urgencias y Hometown Health, la compañía de seguros sin fines de lucro más grande de la región y de propiedad local, Hometown Health. Renown is currently hiring great physicians, nurses and associates for careers in service; apply at renown.org/careers and volunteers to assist patients and their families at renown.org/about/volunteers. About University of Nevada, Reno The University of Nevada, Reno, is a public research university that is committed to the promise of a future powered by knowledge. Nevada’s land-grant university founded in 1874, the University serves 21,000 students. The University is a comprehensive, doctoral university, classified as an R1 institution with very high research activity by the Carnegie Classification of Institutions of Higher Education. Additionally, it has attained the prestigious “Carnegie Engaged” classification, reflecting its student and institutional impact on civic engagement and service, fostered by extensive community and statewide collaborations. More than $800 million in advanced labs, residence halls and facilities has been invested on campus since 2009. It is home to the University of Nevada, Reno School of Medicine, and Wolf Pack Athletics, maintains a statewide outreach mission and presence through programs such as the University of Nevada, Reno Extension, Nevada Bureau of Mines and Geology, Small Business Development Center, Nevada Seismological Laboratory, and is part of the Nevada System of Higher Education. Through a commitment to world-improving research, student success and outreach benefiting the communities and businesses of Nevada, the University has impact across the state and around the world. For more information, visit unr.edu.

Leer más About Celebrating More Than 150 Years of Nursing, First Nevada Hospital and Nursing School Award First Jerry Smith Student Tuition Support

Lanzada en asociación con el Desert Research Institute, una nueva investigación del proyecto Healthy Nevada Project® determina que un diagnóstico confirmado no siempre produce cambios en el cuidado del paciente. El hecho de entregar a las personas información de salud que pueda cambiar sus vidas no garantiza que las personas, o sus proveedores de atención médica, actuarán en consecuencia. La educación de seguimiento y las conversaciones sobre los planes de cuidado ejecutables con los pacientes y sus médicos son los próximos pasos clave, de acuerdo con la nueva investigación del Healthy Nevada Project. El Healthy Nevada Project es un proyecto de investigación y detección genética que se lanzó en 2016 como una asociación entre DRI y Renown Health. El proyecto ahora tiene más de 50,000 participantes y cuenta con secuenciación genética proporcionada por Helix. Entre septiembre de 2018 y septiembre de 2020, el Healthy Nevada Project notificó exitosamente a 293 participantes que estaban genéticamente en riesgo de desarrollar cáncer de pecho y ovario, síndrome de Lynch o hipercolesterolemia familiar hereditarios, tres afecciones genéticas comunes conocidas colectivamente como afecciones de Nivel 1 de los Centros para el Control y la Prevención de Enfermedades (Centers for Disease Control and Prevention, CDC). En un estudio publicado hoy en Frontiers in Genetics, los científicos del Healthy Nevada Project analizaron qué impacto tuvo el hecho de notificar a un paciente sobre un resultado positivo para una condición de Nivel 1 de los CDC en el cuidado que recibió el paciente en los meses y años posteriores. Según sus resultados, entre los 293 participantes del Healthy Nevada Project que fueron notificados del riesgo genético de desarrollar una afección del Nivel 1 de los CDC, el 71 % de participantes con registros médicos electrónicos compartieron sus hallazgos con los proveedores de atención médica. Sin embargo, solo el 30 % de los registros médicos electrónicos de estos pacientes contenía documentación del diagnóstico genético, y solo el 10 % de los pacientes examinados experimentó un posible cambio en el cuidado después de recibir los resultados de su examen de detección genético. “El Healthy Nevada Project se implementó con un enfoque ‘sin intervención’ en el que los participantes reciben sus hallazgos y deciden con quiénes y cuándo desean compartirlos. Los hallazgos no se agregaron automáticamente a sus registros médicos electrónicos”, explicó el Dr. Gai Elhanan, científico de datos médicos en DRI y coautor del estudio. “Lo que estamos aprendiendo ahora es que para garantizar que los hallazgos genéticos importantes se integren en el régimen de cuidado, es importante que su incorporación en los registros médicos electrónicos forme parte del estudio”. Este estudio se basa en investigaciones anteriores del Healthy Nevada Project publicadas en Nature Medicine. En ellas se demuestra la importancia de realizar exámenes de detección para las afecciones del Nivel 1 de los CDC, las cuales afectan a aproximadamente a 1 de cada 75 personas y se pueden mitigar e incluso se puede evitar que se conviertan en enfermedades cuando se detectan en forma temprana. Este estudio determinó que hasta el 90 % de los casos con afecciones del Nivel 1 de los CDC no son detectados por los proveedores clínicos en las evaluaciones y los exámenes de detección que se realizan durante las visitas de cuidado clínico habitual. Durante el estudio actual, los científicos del Healthy Nevada Project descubrieron que el 19 % de participantes estudiados ya había desarrollado una de las afecciones del Nivel 1 de los CDC y, por lo tanto, podrían haberse beneficiado de una notificación más temprana sobre su afección. El equipo del estudio espera que sus hallazgos estimulen a los residentes de Nevada a obtener pruebas genéticas para estas afecciones relativamente comunes. Incluso si las personas son mayores o ya han sufrido enfermedades relacionadas con estas afecciones, las pruebas también podrían ser beneficiosas para los hermanos, los niños y los nietos que también pueden estar en riesgo y que posteriormente podrían someterse a exámenes de detección en caso de un hallazgo positivo. El equipo del estudio también incita a informar a los proveedores de atención médica sobre la importancia de incorporar diagnósticos genéticos en las recomendaciones farmacéuticas (por ejemplo, para la hipercolesterolemia familiar) y de tratamiento a los pacientes. “Como resultado de este análisis, los médicos de Renown Health y los investigadores del Healthy Nevada Project han logrado cambios significativos, lo que incluye la obtención del consentimiento informado de los participantes para incorporar hallazgos positivos de sus informes genéticos directamente en su registro médico electrónico”, explicó Daniel Kiser, M.S., científico auxiliar de investigación de ciencia de datos en DRI y coautor del estudio. “Esto ayudará tanto a los participantes como a sus proveedores de cuidado clínico, y a todo el estado a maximizar los beneficios a largo plazo de los exámenes de detección genéticos voluntarios basados en la población del Healthy Nevada Project”. Información adicional: El texto completo del estudio, Incomplete Penetrance of Population-Based Genetic Screening Results in Electronic Health Record, está disponible en Frontiers in Genetics: https://www.frontiersin.org/articles/10.3389/fgene.2022.866169/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Genetics&id=866169. Este proyecto fue financiado por Renown Health, fundación de Renown Health y la Oficina de Desarrollo Económico del Gobernador de Nevada. Entre los autores del estudio se incluyen Gai Elhanan (DRI), Daniel Kiser (DRI), Iva Neveux (DRI), Shaun Dabe (Renown Health), Alexander Bolze (Helix), William Metcalf (DRI), James Lu (Helix) y Joseph Grzymski (DRI/Renown Health). Para obtener más información sobre el Healthy Nevada Project® o para solicitar un examen de detección genético, visite: https://healthynv.org/ Acerca del DRI El Desert Research Institute (DRI) es un reconocido líder mundial en investigación ambiental básica y aplicada. Comprometidos con la excelencia e integridad científicas, el cuerpo docente del DRI, los estudiantes que trabajan juntos y el personal han desarrollado conocimientos científicos y tecnologías innovadoras en proyectos de investigación en todo el mundo. Desde 1959, la investigación de DRI ha profundizado el conocimiento científico sobre temas que van desde el impacto de los seres humanos en el medioambiente hasta el impacto del medioambiente en los seres humanos. Los hallazgos científicos impactantes y las soluciones inspiradoras del DRI apoyan la economía diversa de Nevada, proporcionan oportunidades educativas basadas en la ciencia e informan a legisladores, líderes empresariales y miembros de la comunidad. El DRI tiene campus en Las Vegas y Reno y funciona como el grupo de investigación sin fines de lucro del Sistema de Educación Superior de Nevada. Para obtener más información, visite www.dri.edu. Acerca de Renown Health Renown Health es la red de atención médica integrada de administración local y sin fines de lucro más grande de la región, que presta servicios a Nevada, Lake Tahoe y el noreste de California. Con una fuerza laboral diversa de más de 7,000 empleados, Renown ha fomentado una cultura de excelencia, determinación e innovación de larga data. La organización se compone de un centro de urgencias, dos hospitales de cuidados agudos, un hospital infantil, un hospital de rehabilitación, un grupo médico y una red de atención de urgencias y Hometown Health, la compañía de seguros sin fines de lucro más grande de la región y de propiedad local, Hometown Health. Actualmente, Renown está inscribiendo participantes en el estudio genético de salud poblacional basado en la comunidad más grande del mundo, el Healthy Nevada Project®. Visite renown.org para obtener más información. Acerca de Helix Helix es la compañía líder en genómica y vigilancia viral de la población cuyas operaciones se basan en el cuidado clínico, la investigación y el análisis de datos. Helix permite que los sistemas de salud, las empresas de ciencias biológicas, los pagadores y los socios gubernamentales aceleren la integración de los datos genómicos en el cuidado médico del paciente y en la toma de decisiones de salud pública. Obtenga más información en www.helix.com.

Leer más About Un estudio demuestra la importancia de garantizar el seguimiento del participante y del proveedor después de obtener el resultado de un examen de detección genético

El enfoque basado en la comunidad del Healthy Nevada Project revela que hasta un 90 % de los riesgos de padecer afecciones genéticas de Nivel 1 de los CDC no se detecta cuando se usan pautas de atención clínica. In a new study published today in the journal Nature Medicine, researchers behind the Healthy Nevada Project® suggest that community-based genetic screening has the potential to efficiently identify individuals who may be at increased risk for three common inherited genetic conditions known to cause several forms of cancer and increased risk for heart disease or stroke. En 2018, el Healthy Nevada Project® (el mayor estudio de salud poblacional basado en la comunidad que combina datos genéticos, clínicos, ambientales y sociales) comenzó a notificarles a los participantes del estudio que habían dado su consentimiento sobre ciertas variantes genéticas que los predisponían a padecer las afecciones genéticas de Nivel 1 de los Centros para el Control y la Prevención de Enfermedades (Centers for Disease Control and Prevention, CDC). The study focused on identifying carriers of these conditions, which include Hereditary Breast and Ovarian Cancer, Lynch Syndrome, and Familial Hypercholesterolemia, because they are the most common conditions and early detection and treatment could significantly lower morbidity and mortality. Los resultados iniciales de casi 27,000 participantes del estudio mostraron que el 90 % de los portadores de las afecciones genéticas de Nivel 1 de los CDC no había sido previamente identificado en un entorno clínico. The authors conclude that population genetic screening would identify at-risk carriers not identified during routine care. “Our first goal was to deliver actionable health data back to the participants of the study and understand whether or not broad population screening of CDC Tier 1 genomic conditions was a practical tool to identify at-risk individuals,” explained Joseph Grzymski, Ph.D., the principal investigator of the Healthy Nevada Project®, a research professor at the Desert Research Institute (DRI), chief scientific officer for Renown Health and lead author of the study. “Now, two years into doing that, it is clear that the clinical guidelines for detecting risk in individuals are too narrow and miss too many at risk individuals.” Del grupo de 26,906 participantes del Healthy Nevada Project® que el equipo de investigación de Grzymski estudió, 358 (el 1.33 %) eran portadores de afecciones de Nivel 1 de los CDC. Sin embargo, solo el 25 % de esas personas cumplían las pautas clínicas para realizarse exámenes de detección genética. Además, más del 20 % de los portadores ya tenía un diagnóstico de enfermedad relacionada con la afección genética subyacente. “We’re at a point now where it’s possible to do clinical-grade genetic screening at population-scale,” added James Lu, M.D. Ph.D., co-founder and chief scientific officer of Helix and senior co-author of the study. “What this study demonstrates is the potential impact of doing so. By making genetic screening available more broadly, we can help the millions of Americans who are unaware that they are living at increased risk for highly actionable, genetic conditions take action.” En particular, el estudio descubrió que de los 273 participantes que eran portadores de las afecciones genéticas de Nivel 1 de los CDC y que tenían información de registros clínicos, solo 22 personas mostraron sospechas previas de tener estas afecciones genéticas subyacentes. “For the first time, we are providing information at the individual level so study participants can make lifesaving changes to reduce their risk based on their genetics,” said Anthony Slonim, M.D., Dr.PH., FACHE, president and CEO of Renown Health and co-director of the Project® study. “We’re conducting research on the community level to develop leading-edge research on health determinants for entire neighborhoods, states and eventually, the country. Returning these results allows us to understand the prevalence of genetically programmed diseases and illnesses that we have here in Nevada and ensure we are providing the best prevention and care plans. For the individual, the return of results can be life changing.” According to the CDC, early detection and intervention of the Tier 1 genetic conditions could have a meaningful potential for clinical action ability and a positive impact on public health. El Healthy Nevada Project®, que se lanzó en 2016, ofrece pruebas genéticas gratuitas a todos los residentes de Nevada, mayores de 18 años, interesados en obtener más información sobre su salud y perfil genético. Con más de 50,000 participantes del estudio inscritos en cuatro años, el Healthy Nevada Project® se ha convertido en el estudio genético de más rápida inscripción del mundo. For more about the Healthy Nevada Project® please visit healthynv.org     Renown Institute for Health Innovation is a collaboration between Renown Health – a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California; and the Desert Research Institute – a recognized world leader in investigating the effects of natural and human induced environmental change and advancing technologies aimed at assessing a changing planet. Renown IHI research teams are focused on integrating personal healthcare and environmental data with socioeconomic determinants to help Nevada address some of its most complex environmental health problems; while simultaneously expanding the state’s access to leading-edge clinical trials and fostering new connections with biotechnology and pharmaceutical companies. Learn more at Healthynv.org. Helix is the leading population genomics company operating at the intersection of clinical care, research, and genomics. Its end-to-end platform enables health systems, life sciences companies, and payers to advance genomic research and accelerate the integration of genomic data into clinical care. Powered by one of the world's largest CLIA / CAP next-generation sequencing labs and its proprietary Exome+Ⓡ assay, Helix supports all aspects of population genomics including recruitment and engagement, clinically actionable disease screening, return of results, and basic and translational research. In response to the COVID-19 public health crisis, Helix has launched a sensitive and scalable end-to-end COVID-19 test system to meet the needs of health systems, employers, governments, and other organizations across the country. Obtenga más información en www.helix.com.

Leer más About Los exámenes de detección genética poblacionales demuestran que identifican de manera eficiente un aumento en el riesgo de padecer enfermedades hereditarias

Funds used to stand up virtual screenings, purchase telehealth equipment, provide virtual care and enhance remote monitoring services to help keep the community safe Renown Health Foundation announced today that it is the recipient of a $977,720 grant from the Federal Communications Commission (FCC) for its COVID-19 Telehealth Program. The funding will be used to offset the expenses of various telehealth programs implemented during the current COVID-19 pandemic. A portion of the grant will also be used to help Renown expand its remote monitoring capabilities, reshaping the way patients receive care from the comfort of their homes.  “Virtual technology is shaping the future of medicine and how we deliver care to our patients,” said Tony Slonim, MD, DrPH, president and CEO of Renown Health. “It’s convenient, fast, reliable and accessible to everyone with a mobile device. Amid the COVID-19 pandemic, I have witnessed the incredible power of technology to ensure our patients receive quality care when and where they need it. I look forward to the future of digital health as we continue expanding our virtual service offerings, contributing to a happier, healthier community.” Renown will use a portion of the funding to offset expenses incurred to establish the virtual COVID-19 visit screenings for the pandemic. These on-line, virtual visits allowed individuals with signs of respiratory illness across Nevada and California to be screened by a care provider for COVID-19. Previously, a screening was required for patients to receive a test, making this a critical tool to help our region flatten the curve.   The grant will also support Renown’s efforts to introduce a dedicated platform to enable all specialists and urgent care providers to deliver virtual care to patients, if their care needs can be met through a virtual platform. These visits have been essential as community members continue to practice physical distancing and many live in rural communities. “We are incredibly thankful for the support of the FCC, as this grant has already played a huge role in the way our community receives the care they need and deserve,” said Renown’s chief development officer, Greg Walaitis. “During the COVID-19 pandemic and beyond, it will help us ensure all patients in our area have access to care from their homes or nearby locations.”  Furthermore, the grant will support some of the technology and equipment used in Renown’s Alternate Care Site located in its Mill Street Parking structure.  “Though we are fortunate our Alternate Care Site remains unused today, the facility is equipped with computers and tablets embedded with telehealth solutions, all supported by the FCC grant,” said Renown’s director of telehealth, Mitchell Fong. “This technology would allow our providers to treat and monitor our patients with COVID-19 without being exposed to the virus, so they can remain healthy and a vital part of the care team where they are needed most.”  Renown purchased video conference software licenses to support these virtual programs. Aside from connecting patients to care providers, the technology was used to enhance a patient’s hospital stay and make them feel more emotionally comfortable and connected.  “Before initiating our Patient Supporter program, we weren’t allowing visitors in our hospitals due to the pandemic to help keep patients, staff and our community safe,” said Fong. “The purchase of video conferencing licenses helped patients from all hospital units connect with loved ones via videoconferencing calls facilitated by their care providers. We know these interactions are an important aspect of a patient’s healing experience, and the FCC grant made it possible for countless patients to stay in touch with their external support networks.”  Finally, the FCC funding will allow Renown to expand and enhance its remote monitoring services, particularly for hospital patients who have recovered from COVID-19. Renown is currently exploring tools for providers to virtually – and seamlessly – monitor and track their patient’s oxygen levels, among other vitals, once they go home. This will aid in smooth and efficient transitional care, as the recovery period after a patient is discharged from the hospital is considered exceptionally critical.       About Renown Health   Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving northern Nevada, Lake Tahoe and northeast California. Renown es uno de los mayores empleadores privados de la región y cuenta con una fuerza laboral de más de 7,000. It comprises three acute care hospitals, Renown Children’s Hospital, Renown Rehabilitation Hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown has a long tradition and commitment to continually improve the care and the health of our community. For more information, visit renown.org.

Leer más About Renown Health Awarded Nearly 1 Million Grant from the FCC

Juntos, realizarán pruebas a más de 30,000 participantes del estudio elegibles antes de 2023 para determinar el riesgo de cirrosis y enfermedades relacionadas con el hígado. Renown Institute for Health Innovation (IHI) announced today that the organization and Gilead Sciences, Inc. will be joining forces with Siemens Healthineers to offer the Enhanced Liver Fibrosis (ELF™) Test to people with risks for nonalcoholic steatohepatitis (NASH) enrolled in the Healthy Nevada Project (HNP). The ELF Test will help identify people most at risk for progressing to cirrhosis and liver-related outcomes and allow healthcare providers to intervene before irreparable damage occurs. This noninvasive blood test uses three serum biomarkers to create an ELF score from a predefined algorithm, which can be used by doctors to help evaluate if a patient requires increased medical care and monitoring for their condition. La enfermedad de hígado graso no alcohólico (EHGNA), que incluye la EHNA, es frecuente en Nevada y está subdiagnosticada, y probablemente afecte a más de 500,000 adultos en nuestro estado. If undetected and untreated, NASH can result in liver cirrhosis and may require liver transplantation or lead to death. Hay más de 12,000 personas en la lista de espera para trasplante de hígado en los EE. UU. y esta cifra continúa aumentando debido al incremento en la prevalencia de la EHGNA. “Thanks to important data collected through our Nonalcoholic Steatohepatitis Liver Disease Genome Atlas study, we now know that NASH is prevalent in the state of Nevada,” said Tony Slonim, M.D., DrPH, FACHE, president and CEO of Renown Health. “We are proud to expand our partnership with Gilead and begin working with Siemens Healthineers to improve health of those with liver disease and to take early detection one step further by offering Enhanced Liver Fibrosis, ELF testing for patients of Renown Health. This test provides our team of highly-skilled physicians an advanced, noninvasive method to actively assess dynamic liver fibrosis in study participants and intervene whenever necessary, contributing to a healthier Nevada.”  “Gilead believes that noninvasive tests, including the ELF Test, will help improve the experience of people living with NASH. These tests may help to diagnose liver disease, monitor disease progression and evaluate responses to treatment without the requirement for liver biopsy,” said Rob Myers, MD, Vice President, Liver Fibrosis Clinical Research at Gilead Sciences. “The ELF Test has proven itself to be a valuable tool in NASH management and we hope this partnership will further support its use in routine care.”  “We are very pleased that NASH patients in the Healthy Nevada Project now have access to the ELF Test which offers clinically useful prognostic information for their condition with the convenience of a simple blood test. Using our advanced laboratory expertise together with Renown IHI and Gilead, we can work towards better understanding of NASH and liver disease in a representative patient population,” said Sebastian Kronmueller, Head of Molecular Diagnostics at Siemens Healthineers. “We launched the Healthy Nevada Project to help people understand more about their health, to identify serious health risks, and to give people access to innovations like the ELF Test, so they can live their best lives,” said Renown’s chief scientific officer, Dr. Joseph Grzymski, who is also a research professor at the Desert Research Institute and principal investigator of the Healthy Nevada Project. Es increíblemente gratificante poder informar hallazgos clínicos para ayudar a nuestros 50,000 participantes voluntarios del estudio y asistir a los proveedores de atención médica a ayudar a sus pacientes”. La provisión de la prueba de ELF se basa en una colaboración estratégica anunciada previamente entre el Renown IHI y Gilead en julio de 2019. Esta sociedad en curso tiene como objetivo recopilar y analizar datos de salud genéticos y electrónicos anónimos de 60,000 participantes del estudio elegibles con el fin de mejorar la comprensión de la EHGNA y la EHNA y para potencialmente orientar el desarrollo de opciones de tratamiento para estas enfermedades. Acerca de la EHGNA y la EHNA La EHGNA es una acumulación de grasa en el hígado en personas que no tienen antecedentes de abuso de alcohol. Es normal que el hígado contenga algo de grasa, pero si más del 5 por ciento del contenido hepático es grasa, se considera hígado graso (esteatosis). NASH is the most severe form of NAFLD in which a person has liver cell damage and inflammation of the liver. Inflammation and liver cell damage can cause fibrosis, or scarring of the liver, and can cause decreased liver function (1). The symptoms of NASH are often silent or non-specific, making it difficult to diagnose. Aproximadamente, un tercio de las personas con EHNA desarrollan cirrosis o daño hepático irreversible (2). About the ELF™ Test The ELF Test is a noninvasive blood test that can quickly identify which patients are at an elevated risk for developing cirrhosis and other liver-related clinical events (LREs). In contrast to standard liver enzyme tests that reflect liver damage that has already occurred, the ELF Test combines three serum direct biomarkers of active fibrosis. The ELF Test algorithm measures each of these biomarkers to create an ELF score, which can be used as an aid to assess the risk for future disease progression. Doctors may use this ELF score to help evaluate if a patient requires increased medical care and monitoring for their condition. Individuals interested in determining their risk for NASH and its progression are encouraged to enroll in the Nonalcoholic Steatohepatitis Liver Disease Genome Atlas study. Those who have already consented and participated in the study will be contacted with more information on how to receive an ELF blood test. Para obtener más información o para inscribirse, comuníquese a la casilla de correo RenownIHI@renown.org o al teléfono (775) 982-6914. The Enhanced Liver Fibrosis (ELF™) Test kit is not available for sale in the U.S. Product availability may vary from country to country and is subject to varying regulatory requirements.  In the U.S., the ELF Testing Service is available from Siemens Healthcare Laboratory, LLC (SHL), a CLIA-certified laboratory located in Berkeley, Calif. The ELF Testing Service, including the establishment of performance characteristics, was developed by SHL. The ELF Test has not been cleared or approved by the U.S. Food and Drug Administration. SHL is regulated under CLIA as qualified to perform high complexity testing. The ELF Test is used for clinical purposes and should not be regarded as investigational use only or research use only. About Renown Health Renown Health is the region’s largest, locally owned and governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Con una fuerza laboral diversa de más de 7,000 empleados, Renown ha fomentado una cultura de excelencia, determinación e innovación de larga data. La organización se compone de un centro de urgencias, dos hospitales de cuidados agudos, un hospital infantil, un hospital de rehabilitación, un grupo médico y una red de atención de urgencias y Hometown Health, la compañía de seguros sin fines de lucro más grande de la región y de propiedad local, Hometown Health. Renown’s institute model addresses social determinants of health and includes: Child Health, Behavioral Health & Addiction, Healthy Aging and Health Innovation. Clinical institutes include: Cancer, Heart and Vascular Health, Neurosciences and Robotic Surgery. Actualmente, Renown está inscribiendo participantes en el estudio genético de salud poblacional basado en la comunidad más grande del mundo, el Healthy Nevada Project®. For more information visit, renown.org. About the Renown Institute for Health Innovation Renown Institute for Health Innovation is a collaboration between Renown Health - a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California; and the Desert Research Institute - a recognized world leader in investigating the effects of natural and human-induced environmental change and advancing technologies aimed at assessing a changing planet. Renown IHI research teams are focused on integrating personal healthcare and environmental data with socioeconomic determinants to help Nevada address some of its most complex environmental health problems; while simultaneously expanding the state’s access to leading-edge clinical trials and fostering new connections with biotechnology and pharmaceutical companies. Learn more at healthynv.org. Renown Health es la red de atención médica más completa e integrada de Nevada y mantiene registros médicos electrónicos para 1.02 millones de pacientes registrados. En 2016, Renown Health y el Desert Research Institute crearon el Healthy Nevada Project (HNP), el primer estudio de salud poblacional basado en la comunidad del país. En 2017, el HNP comenzó una sociedad con Helix para aprovechar sus servicios de salud poblacional, la secuenciación Exome+™ y las herramientas de participación del consumidor. The HNP is now an ongoing collaboration between Renown IHI, the Desert Research Institute, a global leader in environmental data and applied research, and Helix, a personal genomics company. HNP combines genetic, environmental, social and clinical data to address individual and community health needs with the goal of improving health across the state and the nation. El HNP actualmente tiene más de 60,000 participantes. For more information, visit healthynv.org.  About Siemens Healthineers Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostic, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers ability to provide high-quality, efficient care to patients. En el año fiscal 2020, que finalizó el 30 de septiembre de 2020, Siemens Healthineers, que tiene aproximadamente 54,000 empleados en todo el mundo, generó ingresos por €14.5 mil millones y un EBIT ajustado de €2.2 mil millones. Encontrará más información disponible en www.siemens-healthineers.com.Media Contacto de Siemens Healthineers: Lance LongwellM: 610-448-6341E: lance.longwell@siemens-healthineers.com

Leer más About Renown Institute Expands Partnership to Offer ELF Testing